{"filing":{"accession_number":"0001493152-26-037254","cik":"0001326706","ticker":"FEED","company_name":"ENvue Medical, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315226037254/form8-k.htm"},"events":[{"id":27068,"run_id":24639,"accession_number":"0001493152-26-037254","anchor_item_number":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"ENvue Medical entered into a Common Shares Purchase Agreement on August 12, 2026, establishing a committed equity facility of up to $50 million whereby the Company can sell common stock to an institutional investor at 90% of the three-day volume-weighted average price. This is a classic at-the-market (ATM) or committed equity offering structure that allows the Company to raise capital through dilutive equity issuance at its discretion. The filing also discloses a Second Amendment to a prior Series H Preferred Stock purchase agreement increasing additional investment rights to $59 million. Both transactions represent material dilutive equity issuances typical of small- and mid-cap companies raising capital.","company_name":"ENvue Medical, Inc.","ticker":"FEED","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":28437,"accession_number":"0001493152-26-037254","item_number":null,"item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"ENvue Medical entered into a Common Shares Purchase Agreement on August 12, 2026, establishing a committed equity facility of up to $50 million whereby the Company can sell common stock to an institutional investor at 90% of the three-day volume-weighted average price. This is a classic at-the-market (ATM) or committed equity offering structure that allows the Company to raise capital through dilutive equity issuance at its discretion. The filing also discloses a Second Amendment to a prior Series H Preferred Stock purchase agreement increasing additional investment rights to $59 million. Both transactions represent material dilutive equity issuances typical of small- and mid-cap companies raising capital.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:30:38.355770+00:00","company_name":"ENvue Medical, Inc.","ticker":"FEED","filing_date":"2026-08-12"}]}